Immunomedics Inc (IMMU) Stock News
NASDAQ:IMMU - Nasdaq -
IMMU Latest News, Press Relases and Analysis
Gilead Wants Ex-Executive to Repay Millions for Insider Probe
Gilead Sciences Inc. wants to claw back more than $4 million in legal fees the former chief financial officer of its Immunomedics unit racked up during a federal probe of insider trading allegations.
Mentions: GILD
Gilead, Biogen Lead Biotechs That ‘Need to Do Deals’ for Growth
Biotech mergers should pick up steam this year as cash-rich companies whose shares stumbled through 2020 -- like Amgen Inc. and Gilead Sciences Inc. -- look to replenish wavering pipelines.
Pandemic, Democratic Wins Leave Drug Industry at Crossroads
In 2020, the pharmaceutical industry raced to develop shots against a deadly new virus sweeping the globe -- and succeeded, in record time. They did it while navigating the pandemic themselves, managing operations and supply chains amid profound disruption.
A Trigger to Get Long: Three Inside Up, RSI, Moving Average Trigger in Immunomedics Inc
The Techncial Trigger Driven Stock Trade in Immunomedics Inc (NASDAQ:IMMU) .
7 Stocks That Look Like Great Buyout Targets
Companies are always seeking growth through mergers and acquisitions, so investors could pick buyout stocks before the market does
Mentions: GILD
What's Driving Gilead Sciences' Growth-Through-Acquisition Strategy
Here's why the company known for antiviral treatment has been busy buying cancer drug developers.
Mentions: GILD
Should You Buy Immunomedics Before the Gilead Sciences Acquisition Closes?
The company's recent acquisition at a lofty premium looks similar to other Gilead deals. That could mean one of two things for investors.
Mentions: GILD
Pre-earnings Bullish Momentum Pattern and Trigger in Immunomedics Inc
The Techncial Trigger Driven Stock Trade in Immunomedics Inc (NASDAQ:IMMU) .
Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (...
Gilead Sciences Gets FDA Approval For Covid-19 Treatment Remdesivir
Gilead Sciences got FDA approval for its Covid-19 treatment that already had emergency authorization, sending GILD stock up after hitting 7-year low.
Mentions: GILD
The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 21) Amicus Therapeutics, Inc. (...
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev
Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.
Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma
Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.
Axovant's Gene Therapy Gets Rare Pediatric Disease Status
The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.
Alaska Bought Up Gilead, Lilly, and Wells Fargo Stock. Here’s What It Sold.
Alaska’s Department of Revenue materially increased investments in Gilead Sciences and Eli Lilly stock in the third quarter. It also bought more Wells Fargo and sold Bank of America stock.
Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia
After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.
Regeneron Pharmaceuticals, Gilead Sciences Shares Rise As Their Therapies Used To Treat President
White House doctors' choice of their therapies to treat President Trump for Covid-19 boosted REGN stock and GILD stock early Monday.
Biotech Pulmonx Set to Start Trading
The raised $190 million after pricing its deal above its expected range.
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, RST, IMMU, VAR
NEW YORK, NY / ACCESSWIRE / September 26, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Under the terms of the merger, Cellular Biomedicine
